- 2026-02
- Journal of cosmetic dermatology 25(2)
- Xiaoyue Teng
- Xiaohong Shu
- Wei Huo
- Zhaoxia Li
- Lin Zou
- Li Li
- Xi Wang
Study Design
- Type
- Clinical Trial
- Population
- 33 patients with mild or moderate acne vulgaris
- Methods
- pilot study; treated with Herbal Balance Solution once every 3 days for 4 weeks; acne lesion counts and severity index measured at baseline, Week 2, and Week 4
- Blinding
- Open-label
- Duration
- 4 weeks
- Funding
- Unclear
Objective
Acne is a common skin condition that seriously affects the physical and mental health of patients. In addition to the standard acne treatment, anti-acne skin care products are gradually becoming essential in preventing and treating acne. Herbal Balance Solution contains multiple botanical ingredients with potential anti-inflammatory and barrier-supportive properties. This pilot study aimed to explore the safety and preliminary clinical effects of Herbal Balance Solution in patients with mild-to-moderate acne vulgaris.Methods
Thirty-three patients with mild or moderate acne vulgaris were treated with Herbal Balance Solution once every 3 days for 4 weeks. At baseline (Week 0, W0), Week 2 (W2), and Week 4 (W4), acne lesion counts (total, inflammatory, and non-inflammatory lesions) and the severity index were measured to assess the treatment efficacy, and transepidermal water loss was tested to assess face irritation.Results
The number of closed comedones was significantly reduced (p < 0.01) at each time point after using the test product. Furthermore, the transepidermal water loss rate significantly decreased (p < 0.05). At Week 4, reductions in total inflammatory and non-inflammatory lesion counts were observed and were statistically significant (p < 0.05).Conclusion
In this open-label pilot study, use of Herbal Balance Solution was associated with short-term improvements in acne-related clinical parameters and skin barrier function and was well tolerated in patients with mild-to-moderate acne vulgaris. These preliminary findings warrant confirmation in randomized, vehicle-controlled clinical trials.